title: Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a-new class of compounds exerting antiischemic properties.
abstract: Structural modification of the calcium-antagonist verapamil (1) by replacement of the lipophilic alpha-isopropylacetonitrile moiety by various heterocyclic ring systems has led to a new class of cardiovascular compounds which are characterized by a specific bradycardic activity. These agents reduce heart rate without binding to classical calcium channels or beta-adrenoceptors, interacting instead specifically with structures at the sino atrial node. Therefore they have also been termed sinus node inhibitors. The prototype falipamil (2) has been submitted to further optimization mainly by manipulation of the phthalmidine moiety. This has resulted in a second generation of specific bradycardic agents with increased potency and selectively and prolonged duration of action represented by the benzazepinone-derivative UL-FS 49 (4). Structure-activity relationships within this novel class of compounds have revealed a marked dependence of activity on the substitution pattern of the aromatic rings, the nature of the central nitrogen atom, and the length of the connecting alkyl chains. The crucial role of the benzazepinone ring for bradycardic activity can be best explained by its special impact on the overall molecular conformation.
authors: Department of Chemical Research, Ressort Chemische Forschung, Biberach, West Germany.
authors: M
authors: M
authors: Reiffen
authors: W
authors: W
authors: Eberlein
authors: P
authors: P
authors: Müller
authors: M
authors: M
authors: Psiorz
authors: K
authors: K
authors: Noll
authors: J
authors: J
authors: Heider
authors: C
authors: C
authors: Lillie
authors: W
authors: W
authors: Kobinger
authors: P
authors: P
authors: Luger
mesh_terms: D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000138:chemical synthesis*; D001552:Benzazepines / Q000138:chemical synthesis* / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000138:chemical synthesis*; D002317:Cardiovascular Agents / Q000138:chemical synthesis*; D055598:Chemical Phenomena; D002621:Chemistry; D003327:Coronary Disease / Q000188:drug therapy; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects; D054833:Isoindoles; D008968:Molecular Conformation; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009200:Myocardial Contraction / Q000187:drug effects; D009543:Nifedipine / Q000494:pharmacology; D010797:Phthalimides / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D013329:Structure-Activity Relationship; D014700:Verapamil / Q000494:pharmacology
chemical_list: D000889:Anti-Arrhythmia Agents; D001552:Benzazepines; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D054833:Isoindoles; D010797:Phthalimides; D014700:Verapamil; D009543:Nifedipine; C030532:falipamil; C043636:zatebradine